Clinical Trial Update: Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD). [Phase 2]

View source ↗

Summary

A Phase 2 randomized, double-blind study evaluated the efficacy and safety of losmapimod tablets vs placebo over 24 weeks in adults with chronic obstructive pul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Losmapimod (losmapimod)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 2 | Status: COMPLETED | Results posted: 2018-01-04